Literature DB >> 9032542

Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.

T Miki1, M Sawada, N Nonomura, Y Kojima, A Okuyama, O Maeda, S Saiki, T Kotake.   

Abstract

OBJECTIVE: The antitumor effect of CPT-11, a camptothecin derivative, on two human testicular embryonal carcinomas (TTSC-2 and TTSC-3) heterotransplanted into-nude mice was studied.
MATERIALS AND METHODS: Tumor-bearing nude mice were given daily intraperitoneal injections of the anticancer drugs in 0.1 ml saline 3 times at 3-day intervals. At the end of the experiments tumors were resected and subjected to light-microscopic observation.
RESULTS: When 10, 30 and 50 mg/kg of CPT-11 was administered to tumor-bearing mice intraperitoneally, the antitumor effect of CPT-11 was observed dose-dependently in both TTSC-2 and TTSC-3. When 30 mg/kg of CPT-11 was administered in combination with CDDP, complete tumor regression was observed in both TTSC-2 and TTSC-3 tumors. Histological findings correlated well with the decrease in tumor volume of treated tumors. No mice died after treatment with CPT-11 in a single-agent and combination chemotherapy.
CONCLUSION: Chemotherapy with CPT-11 was an effective and safe method against human testicular tumors heterotransplanted in nude mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032542     DOI: 10.1159/000474425

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.

Authors:  Masatomo Nishikawa; Hideaki Miyake; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2015-06-28       Impact factor: 3.402

2.  Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

Authors:  C Kollmannsberger; O Rick; H Klaproth; T Kubin; H G Sayer; M Hentrich; M Welslau; F Mayer; M Kuczyk; C Spott; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

3.  DNA topoisomerase I and II expression in drug resistant germ cell tumours.

Authors:  D M Berney; J Shamash; J Gaffney; S Jordan; R T D Oliver
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.